Curative Biotechnology, Inc.
Other OTCTotal Valuation
Curative Biotechnology, Inc. carries a market capitalization of 6.20M, placing it among publicly traded companies globally.
| Market Cap | 6.20M |
| Enterprise Value | N/A |
Share Statistics
Curative Biotechnology, Inc. currently has 628.92M shares outstanding.
| Shares Outstanding | 628.92M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -153.44 |
| P/TBV Ratio | -140.66 |
| P/FCF Ratio | -3,827.52 |
| P/OCF Ratio | -3,465.34 |
Financial Position
Curative Biotechnology, Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -2.76 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -239.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Curative Biotechnology, Inc.'s stock has declined approximately -13.4% over the past 52 weeks. The 50-day moving average sits at 0.95, while the 200-day moving average is 1.12.
| Beta (5Y) | N/A |
| 52-Week Price Change | -13.4% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.12 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -3.79M, while operating income came in at -3.80M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -3.80M |
| Pretax Income | -5.17M |
| Net Income | -5.17M |
| EBITDA | -3.79M |
| EBIT | -3.80M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Total book value stands at -17.91M, with working capital of -5.22M providing operational flexibility.
| Cash & Cash Equivalents | 98,035.00 |
| Total Debt | N/A |
| Net Debt | 1.27M |
| Equity (Book Value) | -17.91M |
| Book Value Per Share | -0.03 |
| Working Capital | -5.22M |
Cash Flow
Curative Biotechnology, Inc. produced -488,647.00 in operating cash flow over the past twelve months. After subtracting -46,238.00 in capital expenditures, free cash flow totaled -534,885.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -488,647.00 |
| Capital Expenditures | -46,238.00 |
| Free Cash Flow | -534,885.00 |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.01 |
| FCF Yield | -0.03 |
Stock Splits
Curative Biotechnology, Inc.'s most recent stock split took place on March 23, 2026 with a 150:1 split ratio.
| Last Split Date | 3/23/2026 |
| Split Ratio | 150:1 |
Scores
Curative Biotechnology, Inc. posts an Altman Z-Score of -48.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -48.83 |